Belay Diagnostics published validation data for a cerebrospinal fluid (CSF) genomic profiling assay and signaled intentions to begin billing insurers in the coming months as it seeks to broaden the test’s use beyond oncology to other central nervous system disorders. The company shared analytical and clinical performance metrics to support clinical adoption and reimbursement. Belay’s tumor‑naïve CSF genomic profiling aims to detect genomic alterations in central nervous system malignancies and potentially other neurologic conditions, positioning the test as a tool for both diagnosis and disease monitoring. Management emphasized steps toward payer engagement and scale‑up of billing operations. Payers and clinicians will evaluate the evidence for clinical utility, pathway integration and cost‑effectiveness as Belay moves to commercial deployment. The company’s approach reflects growing interest in liquid and biofluid genomic assays for CNS disease where tissue access is limited. If reimbursed and adopted, the test could change diagnostic workflows for neuro‑oncology and related disorders by offering less invasive molecular profiling options.